These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37186582)

  • 21. Epigenetic signatures in antidepressant treatment response: a methylome-wide association study in the EMC trial.
    Engelmann J; Zillich L; Frank J; Wagner S; Cetin M; Herzog DP; Müller MB; Tadic A; Foo JC; Sirignano L; Braus DF; Dahmen N; Sordon S; Riemenschneider M; Spaniol C; Gasparoni G; Rietschel M; Witt SH; Lieb K; Streit F
    Transl Psychiatry; 2022 Jul; 12(1):268. PubMed ID: 35794104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial.
    Nakajima S; Uchida H; Suzuki T; Watanabe K; Hirano J; Yagihashi T; Takeuchi H; Abe T; Kashima H; Mimura M
    Prog Neuropsychopharmacol Biol Psychiatry; 2011 Dec; 35(8):1983-9. PubMed ID: 21889560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.
    Lam RW; Milev R; Rotzinger S; Andreazza AC; Blier P; Brenner C; Daskalakis ZJ; Dharsee M; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Geraci J; Giacobbe P; Feilotter HE; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; Liotti M; MacQueen GM; McAndrews MP; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Salomons TV; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Kennedy SH;
    BMC Psychiatry; 2016 Apr; 16():105. PubMed ID: 27084692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy outcomes in the MDD-1 India study: First episode major depressive disorder outcomes in antidepressant-treated real-world patients in India.
    Andrade C; De Sousa A; Shah N
    J Psychopharmacol; 2020 Oct; 34(10):1098-1104. PubMed ID: 32684093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Residual cognitive and psychosocial functional impairment in outpatients in Greece who responded to conventional antidepressant monotherapy treatments for major depressive disorder (MDD).
    Papalexi E; Galanopoulos A; Roukas D; Argyropoulos I; Michopoulos I; Douzenis A; Gkolia I; Fotiadis P; Kontis D; Zervas IM
    J Affect Disord; 2022 Oct; 314():185-192. PubMed ID: 35817305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring matrix factorization techniques for significant genes identification of Alzheimer's disease microarray gene expression data.
    Kong W; Mou X; Hu X
    BMC Bioinformatics; 2011; 12 Suppl 5(Suppl 5):S7. PubMed ID: 21989140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence and interaction of genetic, cognitive, neuroendocrine and personalistic markers to antidepressant response in Chinese patients with major depression.
    Bi Y; Ren D; Guo Z; Ma G; Xu F; Chen Z; An L; Zhang N; Ji L; Yuan F; Liu L; Hou B; Yang F; Yu S; Yi Z; Xu Y; He L; Sun X; Dong Z; Wu S; Zhao L; Cai C; Li X; Yu T; Shi Y; He G
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jan; 104():110036. PubMed ID: 32702381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA Methylation in Depression and Depressive-Like Phenotype: Biomarker or Target of Pharmacological Intervention?
    Paoli C; Misztak P; Mazzini G; Musazzi L
    Curr Neuropharmacol; 2022 Nov; 20(12):2267-2291. PubMed ID: 35105292
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship of tryptophan hydroxylase-2 methylation to early-life stress and its impact on short-term antidepressant treatment response.
    Shen T; Li X; Chen L; Chen Z; Tan T; Hua T; Chen B; Yuan Y; Zhang Z; Kuney L; Xu Z
    J Affect Disord; 2020 Nov; 276():850-858. PubMed ID: 32738671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Leveraging Machine Learning Approaches for Predicting Antidepressant Treatment Response Using Electroencephalography (EEG) and Clinical Data.
    Jaworska N; de la Salle S; Ibrahim MH; Blier P; Knott V
    Front Psychiatry; 2018; 9():768. PubMed ID: 30692945
    [No Abstract]   [Full Text] [Related]  

  • 33. Peripheral Alterations in Cytokine and Chemokine Levels After Antidepressant Drug Treatment for Major Depressive Disorder: Systematic Review and Meta-Analysis.
    Köhler CA; Freitas TH; Stubbs B; Maes M; Solmi M; Veronese N; de Andrade NQ; Morris G; Fernandes BS; Brunoni AR; Herrmann N; Raison CL; Miller BJ; Lanctôt KL; Carvalho AF
    Mol Neurobiol; 2018 May; 55(5):4195-4206. PubMed ID: 28612257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
    Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
    World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differentially expressed genes related to major depressive disorder and antidepressant response: genome-wide gene expression analysis.
    Woo HI; Lim SW; Myung W; Kim DK; Lee SY
    Exp Mol Med; 2018 Aug; 50(8):1-11. PubMed ID: 30076325
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
    Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA
    J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning.
    Trivedi MH; Corey-Lisle PK; Guo Z; Lennox RD; Pikalov A; Kim E
    Int Clin Psychopharmacol; 2009 May; 24(3):133-8. PubMed ID: 19318972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: Meta-analysis of three treatment cohorts.
    Ward J; Graham N; Strawbridge RJ; Ferguson A; Jenkins G; Chen W; Hodgson K; Frye M; Weinshilboum R; Uher R; Lewis CM; Biernacka J; Smith DJ
    PLoS One; 2018; 13(9):e0203896. PubMed ID: 30240446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.